Clinical Trial Update: First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody [Phase 1, Phase 2]

View source ↗

Summary

First-in-human imaging study of 89Zr-DFO-daratumumab targeting CD38 in multiple myeloma; study completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• 89Zr-DFO-daratumumab (89Zr-DFO-daratumumab)
• Daratumumab (daratumumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-07-30